178 related articles for article (PubMed ID: 24136145)
1. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
Illidge T; Chan C; Counsell N; Morris S; Scarisbrick J; Gilson D; Popova B; Patrick P; Smith P; Whittaker S; Cowan R
Br J Cancer; 2013 Nov; 109(10):2566-73. PubMed ID: 24136145
[TBL] [Abstract][Full Text] [Related]
2. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Horwitz SM; Hymes K; Goy A; Hernandez-Ilizaliturri FJ; Feldman T; Wegner B; Myskowski PL
Ann Oncol; 2014 Jan; 25(1):206-10. PubMed ID: 24285015
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
4. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Kuzel T; Horwitz S; Demierre MF; Myskowski P; Steckel S
Cancer; 2007 May; 109(9):1799-803. PubMed ID: 17366595
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.
Morita A; Tateishi C; Muramatsu S; Kubo R; Yonezawa E; Kato H; Nishida E; Tsuruta D
J Dermatol; 2020 May; 47(5):443-451. PubMed ID: 32189402
[TBL] [Abstract][Full Text] [Related]
7. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
Duvic M; Kim YH; Zinzani PL; Horwitz SM
Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
[No Abstract] [Full Text] [Related]
8. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.
Mehta N; Wayne AS; Kim YH; Hale GA; Alvarado CS; Myskowski P; Jaffe ES; Busam KJ; Pulitzer M; Zwerner J; Horwitz S
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):20-5. PubMed ID: 22001256
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and vinorelbine treatment in cutaneous T-cell lymphoma in four patients.
Affandi AM; Blumetti TP; Wells J; Hertzberg M; Fernandez-Peñas P
Australas J Dermatol; 2015 Nov; 56(4):294-7. PubMed ID: 25496219
[TBL] [Abstract][Full Text] [Related]
10. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
Heald P; Mehlmauer M; Martin AG; Crowley CA; Yocum RC; Reich SD;
J Am Acad Dermatol; 2003 Nov; 49(5):801-15. PubMed ID: 14576658
[TBL] [Abstract][Full Text] [Related]
11. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials.
Prince HM; McCormack C; Ryan G; Baker C; Rotstein H; Davison J; Yocum R
Australas J Dermatol; 2001 May; 42(2):91-7. PubMed ID: 11309029
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
Zinzani PL; Baliva G; Magagnoli M; Bendandi M; Modugno G; Gherlinzoni F; Orcioni GF; Ascani S; Simoni R; Pileri SA; Tura S
J Clin Oncol; 2000 Jul; 18(13):2603-6. PubMed ID: 10893292
[TBL] [Abstract][Full Text] [Related]
14. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases.
Jidar K; Ingen-Housz-Oro S; Beylot-Barry M; Paul C; Chaoui D; Sigal-Grinberg M; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2009 Sep; 161(3):660-3. PubMed ID: 19438862
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Edelman MJ; Smith R; Hausner P; Doyle LA; Kalra K; Kendall J; Bedor M; Bisaccia S
J Clin Oncol; 2005 Aug; 23(24):5774-8. PubMed ID: 16110034
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
Duvic M; Talpur R; Wen S; Kurzrock R; David CL; Apisarnthanarax N
Clin Lymphoma Myeloma; 2006 Jul; 7(1):51-8. PubMed ID: 16879770
[TBL] [Abstract][Full Text] [Related]
18. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):T547-T554. PubMed ID: 38653368
[TBL] [Abstract][Full Text] [Related]
19. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):547-554. PubMed ID: 38395224
[TBL] [Abstract][Full Text] [Related]
20. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]